Farnesoid X receptor represses matrix metalloproteinase 7 expression, revealing this regulatory axis as a promising therapeutic target in colon cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Farnesoid X receptor represses matrix metalloproteinase 7 expression, revealing this regulatory axis as a promising therapeutic target in colon cancer
Authors
Keywords
-
Journal
JOURNAL OF BIOLOGICAL CHEMISTRY
Volume 294, Issue 21, Pages 8529-8542
Publisher
American Society for Biochemistry & Molecular Biology (ASBMB)
Online
2019-04-10
DOI
10.1074/jbc.ra118.004361
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis
- (2018) Kris V. Kowdley et al. HEPATOLOGY
- Bile acids and colon cancer: Is FXR the solution of the conundrum?
- (2017) Raffaella Maria Gadaleta et al. MOLECULAR ASPECTS OF MEDICINE
- Matrix Metalloproteinases: A challenging paradigm of cancer management
- (2017) Ali Alaseem et al. SEMINARS IN CANCER BIOLOGY
- Differential expression of M3 muscarinic receptors in progressive colon neoplasia and metastasis
- (2017) Kunrong Cheng et al. Oncotarget
- The expanding role of the bile acid receptor farnesoid X in the intestine and its potential clinical implications
- (2016) Laurens J. Ceulemans et al. ACTA CHIRURGICA BELGICA
- Slc10a2-null mice uncover colon cancer-promoting actions of endogenous fecal bile acids
- (2015) Jean-Pierre Raufman et al. CARCINOGENESIS
- Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance
- (2015) Sungsoon Fang et al. NATURE MEDICINE
- Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer
- (2015) Derek C. Marshall et al. PLoS One
- Divergent effects of muscarinic receptor subtype gene ablation on murine colon tumorigenesis reveals association of M3R and zinc finger protein 277 expression in colon neoplasia
- (2014) Kunrong Cheng et al. Molecular Cancer
- The Role of Matrix Metalloproteinases in Colorectal Cancer
- (2014) Anan Said et al. Cancers
- FXR silencing in human colon cancer by DNA methylation and KRAS signaling
- (2013) Ann M. Bailey et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Transcriptional corepressors in cancer
- (2012) Petros D. Grivas et al. CANCER
- Src-Mediated Cross-Talk between Farnesoid X and Epidermal Growth Factor Receptors Inhibits Human Intestinal Cell Proliferation and Tumorigenesis
- (2012) Zhongsheng Peng et al. PLoS One
- Muscarinic receptor agonists stimulate human colon cancer cell migration and invasion
- (2011) Angelica Belo et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Carcinogenicity of deoxycholate, a secondary bile acid
- (2011) Carol Bernstein et al. ARCHIVES OF TOXICOLOGY
- Farnesoid X receptor protects human and murine gastric epithelial cells against inflammation-induced damage
- (2011) Fan Lian et al. BIOCHEMICAL JOURNAL
- Expression of the nuclear bile acid receptor/farnesoid X receptor is reduced in human colon carcinoma compared to nonneoplastic mucosa independent from site and may be associated with adverse prognosis
- (2011) Sigurd Lax et al. INTERNATIONAL JOURNAL OF CANCER
- Bile acids and colon cancer: Solving the puzzle with nuclear receptors
- (2011) Chiara Degirolamo et al. TRENDS IN MOLECULAR MEDICINE
- Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal disease
- (2010) Raffaella M. Gadaleta et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Bile acids: short and long term effects in the intestine
- (2010) Antal Bajor et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Acetylcholine-induced activation of M3 muscarinic receptors stimulates robust matrix metalloproteinase gene expression in human colon cancer cells
- (2009) Guofeng Xie et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities
- (2009) Helmout Modjtahedi et al. ANTI-CANCER DRUGS
- Discovery of XL335 (WAY-362450), a Highly Potent, Selective, and Orally Active Agonist of the Farnesoid X Receptor (FXR)
- (2009) Brenton Flatt et al. JOURNAL OF MEDICINAL CHEMISTRY
- Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
- (2009) Philippe Lefebvre et al. PHYSIOLOGICAL REVIEWS
- Nuclear Bile Acid Receptor FXR Protects against Intestinal Tumorigenesis
- (2008) S. Modica et al. CANCER RESEARCH
- FXR: a metabolic regulator and cell protector
- (2008) Yan-Dong Wang et al. CELL RESEARCH
- Farnesoid X Receptor Deficiency in Mice Leads to Increased Intestinal Epithelial Cell Proliferation and Tumor Development
- (2008) R. R.M. Maran et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation